Preclinical toxicology of bisphosphonates;Toxicologia preclinica de bisfosfonatos

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 93-100

  Mondelo, Nélida ^a   Peluffo, Virginia A ^a   Parma, Mariano D ^a   Cointry, Gustavo R ^b   Capozza, Ricardo F ^b   Ferretti, José L ^b,c   Piccinni, Enrique ^a   Montuori, Esteban ^a  

^a Gador SA   (Argentina)

^b Ctro Estud Metabolismo F   (Argentina)

^c Instituto de Investigaciones Metabolicas   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADVERSE DRUG REACTION; BONE TURNOVER; DRUG SAFETY; HUMAN; OSTEOCLAST; OSTEOLYSIS; PHARMACODYNAMICS; PHARMACOKINETICS; SHORT SURVEY; ANIMAL; ARTICLE; BONE; BONE DENSITY; BONE REMODELING; CHEMICALLY INDUCED DISORDER; DIGESTIVE SYSTEM; DRUG EFFECT; DRUG SCREENING; HYPOCALCEMIA; MOUSE; RABBIT; RAT;

ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; DIGESTIVE SYSTEM; DIPHOSPHONATES; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPOCALCEMIA; MICE; RABBITS; RATS;

EID: 0030764774     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. Fleisch H. En: Bisphosphonates in bone disease. From the laboratory to the patient, The Partenon Publishing group, London, 1995.
2. Weideman M. Toxicity tests in animals: historical perspectives and new opportunities. Environ Health Perspect 1993; 101: 222-5.
3. Roldán EJA , Mondelo N , Piccinni E , Peluffo VA, Montuori E. Olpadronic acid sodium salt. Treatment for Paget's Bone Disease. Treatment for Osteoporosis. Drugs Fut 1995; 20: 1123-7.
4. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996; 18:75-85.
5. Mautalen CA, Casco CA, Gonzalez D, Ghiringhelli GR, Massironi C, Fromm GA, Plantalech L. Side effects of disodium aminohydroxypropylidene diphosphonate (APD) during treatment of bone diseases BMJ 1984; 288: 828-9.
6. Spivacow F, Zanchetta JR, Kerzberg E, Frigeri A, Fiasché R, Roldán EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Ther Res 1996; 57: 123-130.
7. Peter CP, Guy J, Shea M, Bagdon W, Kline WF, Hayes W. Long-term safety of the aminobisphosphonate Alendronate in adult dogs. I. General safety and biomechanical properties of bone. J Pharm Exp Ther 276: 271-6.
8. Cal JC, Cokshott A, Daley Yates PT. Experimental acute renal failure induced by 3 - amino-1-hydroxypropylidene-1,1-bisphosphonate in rodents. En Bach P.H., Nephrotoxicity. Ed. Dekker, New York, 1991; 43-8.
9. Roldán EJA, Kerzberg EM, Castelli G, Pérez Lloret A. Efecto de bajas dosis del pamidronate (APD) oral sobre la calcemia de pacientes osteopénicas u osteoporóticas. Medicina (Buenos Aires) 1996; 56: 133-7.
10. Francis M, Slough C. Acute intravenous infusion of disodium dihydrogen (1- hydroxyethylidene) disphosphonate: mechanism of toxicity. J Pharm Sci 1984; 73: 1097-1100.
11. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Int 1973; 11: 196-214.
12. Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low dose diphosphonate therapy in Paget's disease. Lancet 1984, i: 821-4.
13. Mondelo N, Peluffo VA, Zanchetta JR. Preclinical pharmacology of Olpadronate, a new dimethylated aminobisphosphonate (Abstract). Proc VI World Conference on Clinical pharmacology and Therapeutics, Buenos Aires, Agosto de 1996.
14. Cointry GR, Mondelo N , Zanchetta JR, Montuori E, Ferretti JL. Olpadronate restores ovariectomy-affected bone strength A mechanical, densitometric and tomographic (pQCT) study Bone 1995; 17 (suppl): S 373 - S 8.
15. Ferretti JL, Mondelo N, Capozza RF, Cointry GR, Zanchetta JR, Montuori E. Effects of large doses of Olpadronate (dimethyl-pamidronate) on mineral density, cross-sectional architecture and mechanical properties of rats femurs. Bone 1995; 17 (suppl.): 285 S- 93 S.
16. Mondelo N, Montuori E, Peluffo VA,Capozza RF, Cointry GR, Morillo S, Zanchetta JR, Ferretti JL. Sub-chronic effects of high doses of Mildronate (Olpadronate) on femur densitometric (DEXA), tomographic (pQCT) and mechanical properties in young rats (Abstract). Bone Miner 1994; 25 (suppl 1): S 61
17. 2APD) sobre el fémur de rata in vivo II. Cambios metafisarios tomográficos (Resumen) En: Actas de la XI Reunión Anual de la Asociación Argentina de Osteología y Metabolismo Mineral, Buenos Aires, Noviembre de 1994.
18. Cointry GR, Mondelo N, Peluffo V, Montuori E, Zanchetta JR, Ferretti JL. Femur mass, architecture, mineralization and strength as affected by high doses of Olpadronate in mice. A tomographic (pQCT) and biomechanical study (Abstract). J Bone Miner Res 1996; 11: (Suppl 1): 337 S.
19. Guy JA , Shea M , Peter CP, Morrissey R, Hayes WC. Continuous Alendronate treatment throughout growth, maturation and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993; 53 : 283-8.
20. Fratzl P, Schreiber S, Roschger P, Lafage M-H , Rodan G , Klaushofer K. Effects of sodium fluoride and Alendronate on the bone mineral in minipigs : a small-angle X-ray scattering and backscattered electron imaging study. J Bone Miner Res 1996; 11: 248-53.
21. Ferretti JL, Cointry G, Capozza R, Montuori E, Roldán E, Pérez Lloret A. Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1,1- bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats. Bone Miner 1990; 11: 111-22.
22. Grynpas MD, Acito A, Dumitriu M, Mertz BP, Very JM.Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of APD to dogs. Osteoporosis Int 1992; 2: 74-81.
23. Grynpas MD, Kasra M, Dumitriu M, Nespeca R, Very JM, Mertz BP. Recovery from pamidronate (APD): a two-year study in the dog .Calcif Tissue Int 1994; 55: 288-94.
24. Weile V, Josephsen K, Fejerskov O. Scanning electron microscopy fo final enamel formation in rat mandibular incisors following single injections of 1-hydroxyethylidene -1,1- bisphosphonate. Calcif Tissue Int 1993; 52: 318-24.